Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flurandrenolide

FDA-approved product (ointment, topical), marketed as Cordran, Cordran Sp, Flurandrenolide.

Registered studies
3
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Flurandrenolide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii)
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flurandrenolide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flurandrenolide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Haelan 951 for Menopause Symptoms in Peri- and Postmenopausal Women

    NCT07751029 · start 2026-09-21

    Registered record
    Registry ID
    NCT07751029
    Conditions
    Menopause; Menopause Hot Flashes; Menopause Related Conditions
    Interventions
    Haelan 951
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-09-21
    Completion
    2026-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Menopause Hot Flashes; Menopause Related Conditions
    InterventionHaelan 951
    PhaseNot applicable
    Registry statusRecruiting

  • Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites

    NCT01996930 · start 2013-12

    Registered record
    Registry ID
    NCT01996930
    Conditions
    Peritoneal Dialysis; Continuous Ambulatory Peritoneal Dialysis; End Stage Renal Failure; Chronic Renal Failure
    Interventions
    Haelan tape (steroid impregnated tape); Silver Nitrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12
    Completion
    2017-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeritoneal Dialysis; Continuous Ambulatory Peritoneal Dialysis; End Stage Renal Failure; Chronic Renal Failure
    InterventionHaelan tape (steroid impregnated tape); Silver Nitrate
    PhasePhase 3
    Registry statusCompleted

  • Haelan and Nutrition in Cancer Patients

    NCT00558558 · start 2007-10

    Registered record
    Registry ID
    NCT00558558
    Conditions
    Anorexia; Weight Loss; Cachexia
    Interventions
    Haelan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-10
    Completion
    2009-08
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorexia; Weight Loss; Cachexia
    InterventionHaelan
    PhasePhase 2
    Registry statusTerminated